ArticleMuscle & nerve2015
Demographic and clinical features of inclusion body myositis in North America.
Article in Muscle & nerve, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Diagnostic delay of myositis: an integrated systematic review.Orphanet journal of rare diseases · 2022Pooled it
- Muscle Sonography in Inclusion Body Myositis: A Systematic Review and Meta-Analysis of 944 Measurements.Cells · 2022Pooled it
- Prevalence and Risk of Falls and Fractures in the Idiopathic Inflammatory Myopathies: A Cross-Sectional Study of 470 Patients.Rheumatology and therapy · 2026Article
- Equity in neuromuscular research: a 20-year analysis of race, ethnicity, sex, and age representation.Journal of neurology · 2025Article
- Increasing daily duration of rehabilitation for inpatients with sporadic inclusion body myositis may contribute to improvement in activities of daily living: A nationwide database cohort study.Journal of rehabilitation medicine · 2023Article
- Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis.Neurology · 2023Article
- Pain profile and opioid medication use in patients with idiopathic inflammatory myopathies.Rheumatology (Oxford, England) · 2022Article
- The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.Orphanet journal of rare diseases · 2021Article
- Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study.Neurology · 2021Observational
- Inclusion body myositis: clinical features and pathogenesis.Nature reviews. Rheumatology · 2019Review
- Which nonautoimmune myopathies are most frequently misdiagnosed as myositis?Current opinion in rheumatology · 2017Review
- Predictors of Reduced Health-Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies.Arthritis care & research · 2017Article
- Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016Article
- Myositis Mimics.Current rheumatology reports · 2015Review
- Emerging therapeutic options for sporadic inclusion body myositis.Therapeutics and clinical risk management · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
introductionFew studies of the demographics, natural history, and clinical management of inclusion body myositis (IBM) have been performed in a large patient population. To more accurately define these characteristics, we developed and distributed a questionnaire to patients with IBM.
methodsA cross-sectional, self-reporting survey was conducted.
resultsThe mean age of the 916 participants was 70.4 years, the male-to-female ratio was 2:1, and the majority reported difficulty with ambulation and activities of daily living. The earliest symptoms included impaired use and weakness of arms and legs. The mean time from first symptoms to diagnosis was 4.7 years. Half reported that IBM was their initial diagnosis. A composite functional index negatively associated with age and disease duration, and positively associated with participation in exercise.
conclusionsThese data are valuable for informing patients how IBM manifestations are expected to impair daily living and indicate that self-reporting could be used to establish outcome measures in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.